This suggests that passive immunization with tau antibodies is actually a viable therapeutic focus on and which the CSF level of p-tau262/356 or on the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to watch tau therapeutics in scientific trials.Bienvenue to Singulart. Discover bold, inspiring creations to elevate